Why don’t we have a safe and effective dengue vaccine yet


Recent experiences recommend that Indian scientists from the National Centre for Biological Sciences (NCBS)-Tata Institute of Fundamental Research in Bengaluru, have developed a DNA vaccine candidate towards the dengue virus.

The researchers chosen a a part of crucial viral protein referred to as EDIII from all of the 4 serotypes of the virus. They additionally chosen the NS1 protein from the DENV2 serotype, recognized to trigger extreme dengue.

The examine printed in MedRxiv titled ‘Immune profile and responses of a novel Dengue DNA vaccine encoding EDIII-NS1 consensus design primarily based on Indo-African sequences’ lays down the important thing issues confronted by the scientists in growing a dengue vaccine.

The creator of the examine, Dr Arun Sankaradoss stated, “In the standard vaccines, the entire envelope protein is used, which might result in Antibody Dependent Enhancement — ADE (the place the viral antigen binds to less-effective antibodies making the virus extra effective).”

“We have used only the domain III of the envelope protein from all four serotypes to avoid ADE. We have added the NS1 protein that is known to generate both T cell and B cell response,” he adds.

Prof Sudhir Krishna, senior author and anchor of the dengue vaccine development programme at NCBS in Bengaluru, explains by saying, “We know there are four serotypes of the virus, but what we found was that there were genetic variations within the serotypes. Any sequence with over 6 percent difference is considered to be a different genotype. The team created a consensus sequence that is the same across genotypes as well.”

Furthermore, he emphasizes on the need for more collaborations, “to deliver groups throughout India to work collectively, together with the Translational Health Science and Technology Institute (THSTI), Rajiv Gandhi Centre for Biotechnology and NIMHANS.”

Leave a Reply